Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: JSPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 46.43% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.00M USD | Price to earnings Ratio - | 1Y Target Price 57.9 |
Price to earnings Ratio - | 1Y Target Price 57.9 | ||
Volume (30-day avg) 278608 | Beta 2.24 | 52 Weeks Range 4.11 - 30.70 | Updated Date 04/1/2025 |
52 Weeks Range 4.11 - 30.70 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.89 |
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -1.2278 | Actual -1.62 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.52% | Return on Equity (TTM) -101.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5228876 | Price to Sales(TTM) - |
Enterprise Value -5228876 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.42 | Shares Outstanding 15022100 | Shares Floating 9909493 |
Shares Outstanding 15022100 | Shares Floating 9909493 | ||
Percent Insiders 1.26 | Percent Institutions 105.27 |
Analyst Ratings
Rating 4.64 | Target Price 68.78 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. was founded in 2019. It is a clinical-stage biotechnology company focused on the precision medicine development and commercialization of novel curative therapies.
Core Business Areas
- Hematopoietic Stem Cell Transplant Therapies: Focuses on developing and commercializing conditioning agents to enable curative hematopoietic stem cell transplants, expanding access to these life-saving treatments for more patients.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure typically involves departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Brimostat Mesylate: Brimostat Mesylate is Jasper Therapeutics' lead product candidate. It is a first-in-class anti-c-KIT monoclonal antibody in clinical development as a conditioning agent for hematopoietic stem cell transplantation (HSCT). They are in Phase 2 trials. There is no market share data available as it is in development. Competitors include companies developing alternative conditioning regimens for HSCT such as those with busulfan or TBI.
Market Dynamics
Industry Overview
The industry is focused on developing new and improved therapies for hematopoietic stem cell transplantation (HSCT), and genetic diseases. The market is driven by the need for safer and more effective conditioning regimens.
Positioning
Jasper Therapeutics is positioned as an innovator in the HSCT conditioning space with its anti-c-KIT antibody approach. Its competitive advantage lies in the potential for reduced toxicity and improved outcomes compared to traditional conditioning regimens.
Total Addressable Market (TAM)
The estimated TAM for HSCT conditioning agents is several billion dollars annually. Jasper Therapeutics aims to capture a significant portion of this market by offering a safer and more effective conditioning option.
Upturn SWOT Analysis
Strengths
- Novel anti-c-KIT antibody technology
- Potential for reduced toxicity compared to traditional conditioning regimens
- Experienced management team
- Focus on unmet needs in HSCT
Weaknesses
- Limited cash runway
- Dependence on successful clinical trial outcomes
- Competition from established conditioning regimens
- No approved products on the market
Opportunities
- Expansion of HSCT to treat a wider range of diseases
- Partnerships with leading transplant centers
- Potential for orphan drug designation and accelerated regulatory pathways
- Commercialization of Brimostat Mesylate
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing HSCT conditioning agents
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- BMY
- SANOY
- GSK
Competitive Landscape
Jasper Therapeutics has a differentiated approach with its anti-c-KIT antibody but faces competition from established conditioning regimens like busulfan. Success depends on demonstrating improved efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by advancing its lead product candidate through clinical development.
Future Projections: Future growth projections are dependent on successful clinical trial outcomes, regulatory approval, and commercialization of Brimostat Mesylate.
Recent Initiatives: Recent initiatives include advancing Brimostat Mesylate through Phase 2 clinical trials and exploring potential partnerships.
Summary
Jasper Therapeutics is a clinical-stage company focusing on novel HSCT conditioning agents. Their lead product is in Phase 2 trials, with the potential for reduced toxicity. Key risks include clinical trial outcomes and competition. The company needs to manage cash burn effectively. They operate in a competitive landscape and their success depends on demonstrating improvements over existing regimens.
Similar Companies
- CRIS
- EDIT
- NTLA
- BEAM
Sources and Disclaimers
Data Sources:
- Jasper Therapeutics SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-09-24 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.